Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | ACACA | Q13085 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.37 |
| ▸ | ARG2 | P78540 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3501718 | 0.85 | TSHR (0.43) | ACACBACACAGPR84FFAR1FFAR4 | |
| SCHEMBL3503244 | 0.85 | TSHR (0.43) | ACACBACACAGPR84FFAR1FFAR4 | |
| SCHEMBL290355 | 0.85 | KDM4E (0.44) | ACACBACACAGPR84FFAR1FFAR4 | |
| SCHEMBL525690 | 0.85 | KDM4E (0.44) | ACACBACACAGPR84FFAR1FFAR4 | |
| SCHEMBL3502848 | 0.85 | TSHR (0.43) | ACACBACACAGPR84FFAR1FFAR4 | |
| SCHEMBL3335410 | 0.85 | KDM4E (0.44) | ACACBACACAGPR84FFAR1FFAR4 | |
| SCHEMBL3503242 | 0.85 | TSHR (0.43) | ACACBACACAGPR84FFAR1FFAR4 | |
| SCHEMBL1162330 | 0.85 | KDM4E (0.44) | ACACBACACAGPR84FFAR1FFAR4 | |
| SCHEMBL2223196 | 0.85 | KDM4E (0.44) | ACACBACACAGPR84FFAR1FFAR4 | |
| SCHEMBL10800123 | 0.85 | TSHR (0.43) | ACACBACACAGPR84FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108853105-B | Cosmetic composition, pharmaceutical composition and food composition | 西姆莱斯股份公司 | 2021-10-15 | — | — | CN | disclosed |
| EP-1550429-B1 | EXTERNAL PREPARATIONS FOR SKIN | SHISEIDO CO LTD (JP) | 2010-11-17 | — | — | EP | disclosed |
| US-7445790-B2 | External preparations for skin | SHISEIDO COMPANY, LTD. (JP) | 2008-11-04 | — | — | US | disclosed |
| US-20050180931-A1 | External preparations for skin | SHISEIDO COMPANY, LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1550429-A1 | EXTERNAL PREPARATIONS FOR SKIN | SHISEIDO COMPANY, LTD. (JP) | 2005-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050180931-A1 | External preparations for skin | CUTA, HRH1, CYP24A1 | ACACB 105/4885ACACA 664/4885CYP4F2 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.